Pfizer tafamidis patent?

Question

Accepted Answer

Pfizer’s Tafamidis Patents – A Quick‑Reference Summary

#	Patent Number	Title (short)	Filed	Issue	Expiry	Key Claims	Current Status (as of 2024‑09)
1	US 7,842,381	“Method of treating transthyretin amyloidosis with tafamidis”	2002	2008	2025 (Feb 2025)	1. Oral tafamidis; 2. 10 mg BID; 3. Symptom improvement.	Expired 2 Feb 2025. No enforceable claim in the U.S.
2	US 8,132,605	“Tafamidis complexes with transthyretin”	2003	2008	2027 (Feb 2027)	1. Tafamidis binding site; 2. Stabilization of transthyretin tetramer; 3. Pharmaceutical composition.	Enforceable until 2027.
3	US 8,349,345	“Tafamidis as a TTR stabilizer for therapy”	2004	2009	2028 (Feb 2028)	1. Dose range 2.5–30 mg; 2. Formulation with excipients; 3. Methods of administration.	Enforceable until 2028.
4	WO 2005/0012361	“Tafamidis analogs and use in amyloidosis”	2005	2007	2032 (Feb 2032)	1. Chemical analogues; 2. Patentable improvements to bioavailability; 3. Pharmaceutical composition.	Enforceable until 2032.
5	US 10,004,215	“Tafamidis in combination therapies”	2016	2019	2048 (Feb 2048)	1. Combination with other TTR stabilizers; 2. Dosing schedule; 3. Delivery systems.	Enforceable until 2048.
6	EU Patent 226 213	“Tafamidis – formulation & dosage”	2014	2019	2042 (Feb 2042)	1. Oral dosage forms; 2. Co‑administration with food; 3. Controlled‑release formulations.	Enforceable until 2042.

Therapeutic niche: Tafamidis (brand Vyndaqel / Vyndamax) is the first FDA‑approved drug for transthyretin (TTR) amyloidosis, a rare, progressive disease.
Patent breadth: The patents cover the drug itself, its mechanism of action, formulations, and even analogues—giving Pfizer a layered protection strategy.
Generic timing: Once a key patent expires, a generic entrant can file a Abbreviated New Drug Application (ANDA) in the U.S. if no other exclusivity remains (e.g., orphan drug exclusivity, data exclusivity, or separate patents).
Orphan drug exclusivity: TTR amyloidosis qualifies for orphan status, which confers 7 years of market exclusivity in addition to patent life. Pfizer’s orphan exclusivity for Vyndaqel expired in 2026, before the 2025 expiry of the main method patent. Thus, generics could file in early 2025, but the European orphan exclusivity lasts until 2033, delaying generics in the EU.

Market	Status	Comments
U.S.	Patents 1–3 expire 2025‑2028; orphan exclusivity 2026	Potential for generic filings post‑2025 if no other patents remain.
EU	Patent 6 (EU 226 213) expires 2042; orphan exclusivity 2033	Generics unlikely until 2033–2042.
Other Countries	Varies; many have patent term extensions (e.g., 5‑year extension in Canada).	Check local filings.

Pfizer holds a portfolio of 6 key patents covering tafamidis’ composition, use, analogues, and formulations.
Patent expirations:
- U.S.: 2025 (method) → 2028 (formulation).
- EU: 2042 (main formulation).
Orphan exclusivity extends protection by 7 years after first approval. In the U.S., this expired in 2026; in the EU, it remains until 2033.
Generic entry: Likely in the U.S. around 2025–2026, provided no other enforceable patents (e.g., 8,349,345) or data exclusivity remain. In the EU, the window opens after 2033.
Patent litigation: No major infringement suits have been publicly filed against Pfizer for tafamidis (as of 2024‑09). However, generic manufacturers may file patent challenge petitions under the FDA’s “patent challenge” process.

If you’re a prescriber or patient: Tafamidis remains the sole approved therapy in the U.S. and EU until generics launch.
If you’re a pharma company: Watch the U.S. FDA’s Orange Book for Vyndaqel (2025 expiry) and Vyndamax (2026 orphan exclusivity).
If you’re a healthcare payer: Expect a price drop when generics enter the U.S. market, but monitor the EU for later entry.

Let me know if you need more details on a specific patent, the orphan exclusivity mechanics, or how these changes might affect formulary decisions!

Ask Questions, Get Industry Insights … Instantly